Samyak International's board approved a preferential issue of 4 million equity shares and 4 million warrants at ₹17 each. This fundraising aims to bring in ₹13.6 crore, with participation from promoters and other entities.

Samyak International Ltd

Samyak International Ltd's board has approved a preferential issue of up to 4,000,000 equity shares and 4,000,000 warrants at ₹17.00 per unit.

Reader Takeaway: Capital infusion via preferential issue; potential dilution for existing shareholders.

What just happened

Samyak International Ltd announced that its board has authorized a preferential issue. This involves allotting up to 4,000,000 equity shares and an equal number of convertible warrants, both priced at ₹17.00 per unit. The total potential capital infusion from this issuance is ₹13.6 crore.

The allotment includes participation from the promoter group and several non-promoter entities. The company is undertaking this corporate action under the SEBI (ICDR) Regulations 2018.

Why this matters

This preferential issue is a significant move to raise capital for the company. The ₹13.6 crore infusion will provide Samyak International with additional funds, which can be used for business growth and operational expansion. However, the issuance will also lead to equity dilution for existing shareholders.

The inclusion of both promoter and non-promoter entities suggests continued commitment from insiders and external interest in the company's future at the set price.

The backstory

Samyak International Ltd, a publicly listed entity, periodically seeks capital to fund its strategic initiatives. This preferential issue is part of its ongoing efforts to strengthen its financial position and support its business objectives. The current issuance follows the regulatory framework for such private placements.

What changes now

The company will proceed with the necessary approvals from regulatory bodies and shareholders. Upon successful allotment, the equity base will increase immediately through the issuance of shares, and potentially further upon the conversion of warrants. The company's shareholding pattern will be updated post-allotment.

Risks to watch

Existing shareholders face equity dilution, which could impact their percentage ownership. The ultimate benefit of the capital infusion depends on the company's ability to deploy these funds effectively for profitable growth.

Allottee Overview

The preferential issue involves participation from both the promoter group and other entities. Key promoter group allottees include Sudhir Jain, Sunit Jain, Neha Jain, Samyak Jain, and Virendra Capital Markets Pvt. Ltd. Non-promoter allottees include Volatile Investment and Finance Pvt Ltd, Symphony Sales Pvt. Ltd., Keti-KJ Constructions (India) Limited, KRJ Infraprojects Private Limited, and Aditya Fincom Private Limited.

Warrant Terms

The convertible warrants have a conversion period of 18 months from the date of allotment. A 25% upfront payment is required at subscription, with the remaining 75% due upon exercise. If warrants are not exercised within the tenure, they will lapse, and the upfront payment will be forfeited by the company.

Context metrics

• Securities Issued: Equity Shares & Convertible Warrants
• Issue Price: ₹17.00 per unit
• Total Equity Issue Size: 4,000,000 Shares
• Total Warrant Issue Size: 4,000,000 Warrants
• Aggregate Equity Amount: ₹6.8 crore
• Aggregate Warrant Amount: ₹6.8 crore
• Total Potential Infusion: ₹13.6 crore
• Warrant Conversion Period: 18 Months
• Warrant Upfront Payment: 25%